Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACXP NASDAQ:MAAQ NASDAQ:MURA NASDAQ:SNYR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACXPAcurx Pharmaceuticals$5.31+12.5%$8.21$3.80▼$46.60$8.39M-1.27137,655 shs76,266 shsMAAQMana Capital Acquisition$3.68+1.1%$3.92$5.35▼$10.25$29.90MN/A33,075 shs19,903 shsMURAMural Oncology$2.06-1.0%$2.27$0.95▼$4.74$35.69M31.98 million shs451,232 shsSNYRSynergy CHC$2.98+1.4%$3.23$1.30▼$10.00$28.14MN/A458,053 shs69,652 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACXPAcurx Pharmaceuticals0.00%-7.63%-41.86%-41.00%-89.60%MAAQMana Capital Acquisition0.00%+1.38%-19.65%-6.84%+771.86%MURAMural Oncology0.00%+18.18%-14.05%-24.36%-39.88%SNYRSynergy CHC0.00%-14.29%-22.43%+50.00%+2,840.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACXPAcurx Pharmaceuticals2.4168 of 5 stars3.55.00.00.00.61.70.0MAAQMana Capital AcquisitionN/AN/AN/AN/AN/AN/AN/AN/AMURAMural Oncology2.9402 of 5 stars3.33.00.00.01.82.51.3SNYRSynergy CHC4.3413 of 5 stars3.80.00.00.02.83.33.1Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACXPAcurx Pharmaceuticals 3.00Buy$31.00483.80% UpsideMAAQMana Capital Acquisition 0.00N/AN/AN/AMURAMural Oncology 2.50Moderate Buy$12.00482.52% UpsideSNYRSynergy CHC 3.50Strong Buy$10.00235.57% UpsideCurrent Analyst Ratings BreakdownLatest ACXP, SNYR, MURA, and MAAQ Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/12/2025ACXPAcurx PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$31.00(Data available from 8/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACXPAcurx PharmaceuticalsN/AN/AN/AN/A$0.63 per shareN/AMAAQMana Capital AcquisitionN/AN/AN/AN/AN/AN/AMURAMural OncologyN/AN/AN/AN/A$8.22 per shareN/ASNYRSynergy CHC$33.70M0.83$0.27 per share11.05($1.91) per share-1.56Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACXPAcurx Pharmaceuticals-$14.10M-$10.69N/AN/AN/AN/A-436.83%-192.25%11/11/2025 (Estimated)MAAQMana Capital AcquisitionN/AN/A0.00∞N/AN/AN/AN/AN/AMURAMural Oncology-$128.51M-$8.59N/AN/AN/AN/A-107.76%-87.57%11/12/2025 (Estimated)SNYRSynergy CHC$2.12M$0.387.845.05N/A10.02%-18.56%20.28%N/ALatest ACXP, SNYR, MURA, and MAAQ EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025SNYRSynergy CHC$0.08$0.17+$0.09$0.17$10.80 million$6.74 million8/11/2025Q2 2025ACXPAcurx Pharmaceuticals-$2.00-$1.89+$0.11-$1.89N/AN/A8/4/2025Q2 2025MURAMural Oncology-$1.13-$1.77-$0.64-$2.78N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACXPAcurx PharmaceuticalsN/AN/AN/AN/AN/AMAAQMana Capital AcquisitionN/AN/AN/AN/AN/AMURAMural OncologyN/AN/AN/AN/AN/ASNYRSynergy CHCN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACXPAcurx PharmaceuticalsN/A2.382.38MAAQMana Capital AcquisitionN/AN/AN/AMURAMural OncologyN/A2.872.87SNYRSynergy CHCN/A2.742.41Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACXPAcurx Pharmaceuticals11.53%MAAQMana Capital Acquisition68.44%MURAMural Oncology80.21%SNYRSynergy CHCN/AInsider OwnershipCompanyInsider OwnershipACXPAcurx Pharmaceuticals20.30%MAAQMana Capital AcquisitionN/AMURAMural Oncology2.20%SNYRSynergy CHC56.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACXPAcurx Pharmaceuticals31.58 million1.26 millionOptionableMAAQMana Capital Acquisition18.13 millionN/ANot OptionableMURAMural Oncology11917.32 million16.94 millionOptionableSNYRSynergy CHC409.44 million4.10 millionN/AACXP, SNYR, MURA, and MAAQ HeadlinesRecent News About These CompaniesSynergy CHC's (NASDAQ:SNYR) Earnings Quality Is LowAugust 22 at 10:03 AM | finance.yahoo.comSynergy CHC Corp to Present at the 2025 Gateway Conference on September 4thAugust 21, 2025 | markets.businessinsider.comNew to The Street’s Esteemed Client Synergy CHC Corp. (NASDAQ: SNYR) Announces Nationwide EG America Rollout for FOCUSfactor(R) Focus + Energy EG America, 6th Largest U.S ...August 20, 2025 | palmbeachpost.comPSynergy CHC Corp. (NASDAQ: SNYR) Announces Nationwide EG America Rollout for FOCUSfactor® Focus + EnergyAugust 18, 2025 | taiwannews.com.twTNew to The Street's Esteemed Client Synergy CHC Corp. Announces Nationwide EG America Rollout for FOCUSfactor Focus + Energy EG America, 6th Largest U.S. Convenience Chain ...August 18, 2025 | finanznachrichten.deSynergy CHC announces major distribution with for FOCUSfactor Focus + EnergyAugust 18, 2025 | msn.comSynergy CHC Expands FOCUSfactor Distribution with EG AmericaAugust 18, 2025 | tipranks.comAnalysts Set Expectations for Synergy CHC FY2025 EarningsAugust 18, 2025 | americanbankingnews.comSynergy CHC files to sell 1.28M shares of common stockAugust 15, 2025 | msn.comSynergy Chc EPS Jumps 86 Percent in Q2August 15, 2025 | theglobeandmail.comSynergy CHC Corp.: Synergy CHC Corp Reports Second Quarter 2025 Financial Results and its Tenth Consecutive Quarter of ProfitabilityAugust 14, 2025 | finanznachrichten.deSynergy CHC reports Q2 EPS 17c vs 9c last yearAugust 14, 2025 | msn.comSynergy CHC Corp. Reports Strong Second Quarter 2025 Financial Results with Significant Year-over-Year GrowthAugust 14, 2025 | quiverquant.comQSynergy CHC Corp Reports Second Quarter 2025 Financial Results and its Tenth Consecutive Quarter of ProfitabilityAugust 14, 2025 | globenewswire.comNew to The Street TV Commercial Campaigns Achieve Millions of Views with 87% Average Completion RateAugust 5, 2025 | indystar.comINew to The Street Launches 1,000+ Commercial TV Blitz for Synergy CHC ($SNYR), Makers of Focus Factor(R) – Adds NewsOut Video PR Coverage & NYC #1 Market SaturationAugust 5, 2025 | desmoinesregister.comDJack Ross Buys Handful Of Shares In Synergy CHCAugust 3, 2025 | finance.yahoo.comInsider Buying: Synergy CHC Corp. (NASDAQ:SNYR) CEO Purchases 3,750 Shares of StockAugust 1, 2025 | insidertrades.comSynergy CHC Corp. Announces Second Quarter 2025 Earnings and Conference Call InformationJuly 31, 2025 | manilatimes.netMSynergy CHC Corp. Stock (SNYR) Opinions on Retail Distribution ExpansionJuly 31, 2025 | quiverquant.comQNew MarketBeat Followers Over TimeMedia Sentiment Over TimeACXP, SNYR, MURA, and MAAQ Company DescriptionsAcurx Pharmaceuticals NASDAQ:ACXP$5.31 +0.59 (+12.50%) Closing price 03:59 PM EasternExtended Trading$5.28 -0.02 (-0.47%) As of 05:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.Mana Capital Acquisition NASDAQ:MAAQ$3.68 +0.04 (+1.10%) As of 08/22/2025Mana Capital Acquisition Corp. focuses on engaging in a merger, stock exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination with one or more businesses or entities. It intends to focus on businesses operating in the healthcare, technology, green economy, and consumer products sectors in North America, Europe, and Asia. The company was incorporated in 2021 and is based in Dover, Delaware.Mural Oncology NASDAQ:MURA$2.06 -0.02 (-0.96%) Closing price 04:00 PM EasternExtended Trading$2.06 0.00 (0.00%) As of 05:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops nemvaleukin to treat cutaneous melanoma and advanced solid tumors. The company is also developing engineered interleukin-18 and tumor-targeted interleukin-12 programs. Mural Oncology plc was incorporated in 2017 and is based in Dublin, Ireland.Synergy CHC NASDAQ:SNYR$2.98 +0.04 (+1.36%) As of 03:59 PM EasternSynergy CHC Corp. engages in the marketing and distribution of branded health and wellness products. The company was founded on December 29, 2010 and is headquartered in Westbrook, ME. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas BJ’s Wholesale Club Pulls Back to Trend: It’s Time for an Entry Super Micro Computer Stock Hasn't Priced in Growth Yet Workday: Institutions Are Buying This Stock, Shouldn’t You? Alphabet’s Breakout Potential: From Laggard to AI Leader After Earnings Miss, Walmart Is Still a Top Consumer Staples Play Should You Join Buffett and Invest in Constellation Brands? Why Zuckerberg's META Sales Look More Bullish Than Bearish 3 Dividend Growth Leaders to Buy Now Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access